Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
| ▸ | PON1 | P27169 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718979 | 0.98 | — | — | |
| Iodide SCHEMBL2922211 | 0.96 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1 | |
| Hydrochloric Acid SCHEMBL1048130 | 0.96 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1 | |
| SCHEMBL30070818 | 0.96 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1 | |
| Hydrochloric Acid SCHEMBL29904696 | 0.94 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1 | |
| SCHEMBL3015802 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1 | |
| SCHEMBL4264311 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1 | |
| SCHEMBL925726 | 0.90 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1 | |
| Bromide SCHEMBL14777845 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1 | |
| Sulfuric Acid SCHEMBL17273281 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1HSP90AA1KMT2AAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215165-A1 | LIGNIN-DERIVED CYCLOCARBONATE MONOMERS | VITO NV (BE) | 2025-07-03 | — | — | US | claimed |
| EP-4529538-A1 | LIGNIN-DERIVED CYCLOCARBONATE MONOMERS | Vito NV (BE) | 2025-04-02 | — | — | EP | claimed |
| WO-2023227426-A1 | LIGNIN-DERIVED CYCLOCARBONATE MONOMERS | VITO NV (BE) | 2023-11-30 | — | — | WO | claimed |
| EP-4282870-A1 | LIGNIN-DERIVED CYCLOCARBONATE MONOMERS | Vito NV (BE) | 2023-11-29 | — | — | EP | claimed |
| CN-116465783-A | Method for measuring thermal stability of ionic liquid | 辽宁大学 | 2023-07-21 | — | — | CN | claimed |
| CN-114432736-B | Application of hydroxyl functional ionic liquid in iodine extraction | 辽宁大学 | 2023-05-30 | — | — | CN | claimed |
| CN-115536588-A | Hydroxy glycine functional ionic liquid, preparation method thereof and application thereof in iodine extraction | 辽宁大学 | 2022-12-30 | — | — | CN | claimed |
| CN-114478510-B | Preparation method of nifuratel | 盐城凯利药业有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-113307620-B | Titanium dioxide ceramic slurry for direct-writing forming 3D printing and preparation method thereof | 西华大学 | 2022-07-15 | — | — | CN | claimed |
| CN-114478510-A | Preparation method of nifuratel | 盐城凯利药业有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-2598660-B1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | BIOMATRICA INC (US) | 2017-03-15 | — | — | EP | claimed |
| US-20160338342-A1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | EXACT SCIENCES CORPORATION | 2016-11-24 | — | — | US | claimed |
| US-20130209997-A1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | BIOMATRICA, INC. (US) | 2013-08-15 | — | — | US | claimed |
| EP-2598660-A2 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | Biomatrica, INC. (US) | 2013-06-05 | — | — | EP | claimed |
| EP-2598661-A2 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | Biomatrica, INC. (US) | 2013-06-05 | — | — | EP | claimed |
| US-8411347-B2 | Composition comprising photochromic dyes in an ionic solvent | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2013-04-02 | — | — | US | claimed |
| US-20120052572-A1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | EXACT SCIENCES CORPORATION | 2012-03-01 | — | — | US | claimed |
| WO-2012018639-A2 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN SALIVA AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | BIOMATRICA, INC. (US) | 2012-02-09 | — | — | WO | claimed |
| WO-2012018638-A2 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | BIOMATRICA, INC. (US) | 2012-02-09 | — | — | WO | claimed |
| US-20110013252-A1 | COMPOSITION COMPRISING PHOTOCHROMIC DYES IN AN IONIC SOLVENT | Essilor International (compagnie Generale D'optiqu e (FR) | 2011-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338342-A1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | HNRNPD, HNRNPDL, HNRNPL | SMN1; SMN2 422/4885MEN1 3064/4885HSP90AA1 200/4885 |
| US-20120052572-A1 | COMPOSITIONS FOR STABILIZING DNA, RNA AND PROTEINS IN BLOOD AND OTHER BIOLOGICAL SAMPLES DURING SHIPPING AND STORAGE AT AMBIENT TEMPERATURES | HNRNPD, HNRNPDL, HNRNPL | SMN1; SMN2 422/4885MEN1 3064/4885HSP90AA1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.